Antacid Effects of Chinese Herbal Prescriptions Assessed by a Modified Artificial Stomach Model

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Sep 17

PMID 20845514

Citations 2

Authors

Tsung-Hsiu Wu

I-Chin Chen

Lih-Chi Chen

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the antacid effects of the tonic Chinese herbal prescriptions, si-jun-zi-tang (SJZT) and shen-ling-bai-zhu-san (SLBZS).

Methods: Decoctions of the tonic Chinese herbal prescriptions, SJZT and SLBZS, were prepared according to Chinese original documents. The pH of the prescription decoctions and their neutralizing effects on artificial gastric acids were determined and compared with water and the active controls, sodium bicarbonate and colloidal aluminum phosphate. A modified model of Vatier's artificial stomach was used to determine the duration of consistent neutralization effect on artificial gastric acids. The neutralization capacity in vitro was determined with the titration method of Fordtran's model.

Results: The results showed that both SJZT and SLBZS have antacid effects in vitro. Compared with the water group, SJZT and SLBZS were found to possess significant gastric acid neutralizing effects. The duration for consistent neutralization of SLBZS was significantly longer than that of water. Also, SLBZS and SJZT exhibited significant antacid capacities compared to water.

Conclusion: SJZT and SLBZS were consistently active in the artificial stomach model and are suggested to have antacid effects similar to the active control drugs.

Citing Articles

Utilization patterns and prescription characteristics of traditional Chinese medicine among patients with irritable bowel syndrome in Taiwan.

Gu Y, Lai Y, Chang F, Chen C Front Pharmacol. 2023; 14:1201240.

PMID: 37397480 PMC: 10311911. DOI: 10.3389/fphar.2023.1201240.

Evaluation on the Pharmacological Effect of Traditional Chinese Medicine SiJunZiTang on Stress-Induced Peptic Ulcers.

Chen C, Lee C, Lin P, Hsieh C, Shih H Evid Based Complement Alternat Med. 2013; 2013:186076.

PMID: 23840247 PMC: 3694386. DOI: 10.1155/2013/186076.

References

Berstad A, Weberg R . Antacids in the treatment of gastroduodenal ulcer. Scand J Gastroenterol. 1986; 21(4):385-91. DOI: 10.3109/00365528609015152. View

Fordtran J, COLLYNS J . Antacid pharmacology in duodenal ulcer. Effect of antacids on postcibal gastric acidity and peptic activity. N Engl J Med. 1966; 274(17):921-7. DOI: 10.1056/NEJM196604282741701. View

Vatier J, Harman A, Castela N, Droy-Lefaix M, Farinotti R . Interactions of cimetidine and ranitidine with aluminum-containing antacids and a clay-containing gastric-protective drug in an "artificial stomach-duodenum" model. J Pharm Sci. 1994; 83(7):962-6. DOI: 10.1002/jps.2600830709. View

Maton P, Burton M . Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999; 57(6):855-70. DOI: 10.2165/00003495-199957060-00003. View

Kuang Y, Tan R, Yan W . A study on hemorrheology in patients with spleen Qi deficiency. J Tradit Chin Med. 1988; 8(4):235-8. View

Deakin M, G Williams J . Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Drugs. 1992; 44(5):709-19. DOI: 10.2165/00003495-199244050-00003. View

Wu X . Current concept of Spleen-Stomach theory and Spleen deficiency syndrome in TCM. World J Gastroenterol. 2002; 4(1):2-6. PMC: 4767755. DOI: 10.3748/wjg.v4.i1.2. View

Li S, Chen Z, Yan H, Wang Q . Clinical observation on 80 children with peptic ulcer treated primarily by traditional Chinese medicine. J Tradit Chin Med. 1995; 15(1):14-7. View

Hojgaard L, Mertz Nielsen A, RUNE S . Peptic ulcer pathophysiology: acid, bicarbonate, and mucosal function. Scand J Gastroenterol Suppl. 1996; 216:10-5. DOI: 10.3109/00365529609094555. View

10.

Robert A . Cytoprotection by prostaglandins. Gastroenterology. 1979; 77(4 Pt 1):761-7. View

11.

Vatier J, Lionnet F, Vitre M, Mignon M . A model of an 'artificial stomach' for assessing the characteristics of an antacid. Aliment Pharmacol Ther. 1988; 2(5):461-70. DOI: 10.1111/j.1365-2036.1988.tb00719.x. View

12.

Sung J, Chung S, Ling T, Yung M, Leung V, Ng E . Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995; 332(3):139-42. DOI: 10.1056/NEJM199501193320302. View

13.

Fordtran J, Morawski S, Richardson C . In vivo and in vitro evaluation of liquid antacids. N Engl J Med. 1973; 288(18):923-8. DOI: 10.1056/NEJM197305032881801. View

14.

Richardson P, Hawkey C, Stack W . Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998; 56(3):307-35. DOI: 10.2165/00003495-199856030-00002. View

15.

Sonnenberg A, Schwartz J, Cutler A, Vakil N, Bloom B . Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med. 1998; 158(8):852-60. DOI: 10.1001/archinte.158.8.852. View

16.

Mertz H, Walsh J . Peptic ulcer pathophysiology. Med Clin North Am. 1991; 75(4):799-814. DOI: 10.1016/s0025-7125(16)30412-6. View

17.

Holle G . Pathophysiology and modern treatment of ulcer disease. Int J Mol Med. 2010; 25(4):483-91. DOI: 10.3892/ijmm_00000368. View

18.

Blume H, Donath F, Warnke A, Schug B . Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9):769-84. DOI: 10.2165/00002018-200629090-00002. View

19.

Vatier J, Gao Z, Vitre M, Levy D, Cohen G, Mignon M . Evidence for the interaction between antacid and gastric mucosa using an "artificial stomach" model including gastric mucosa. J Pharmacol Exp Ther. 1992; 263(3):1206-11. View

20.

Vatier J, Vallot T, Vitre M, Mignon M . New approach for the in vitro evaluation of antacids. Arzneimittelforschung. 1990; 40(2 Pt 1):175-9. View